Nasopharyngeal carcinoma (NPC) is a malignancy arising from the malignant epithelial cells in the nasopharyngeal cavity, specifically on the top and side walls. This type of cancer is characterized by its highly invasive nature and exhibits …

Cervical and nasopharyngeal cancers are two well-known pathogen-associated cancers [ 1 ]. Cervical cancer (CC) is the fourth leading cause of death globally in women, accounting for an estimated 604 000 new cases in 2020 with about 90% of these …

Nasopharyngeal carcinoma (NPC) is a relatively rare malignancy in most parts of the world, but the incidence is as much as 50–100 fold higher in ethnic Cantonese Chinese populations in Southern China and Southeast Asia, where it is endemic.

Nasopharyngeal cancer (NPC) is the most common primary neoplasm of the nasopharynx and is mainly found in Asia, especially in southern China. There are approximately 13,000 new cases of the disease diagnosed worldwide each year [ 1 ]. In addition …

Close to 850,000 new head and neck squamous cell carcinoma (HNSCC) cases are diagnosed annually worldwide, and approximately 130,000 of these are nasopharyngeal carcinomas (NPC) [ 1 ]. The NPC incidence is much higher in South-Asia than in Europe …

Concurrent chemoradiotherapy (C-CRT) is currently considered the gold standard treatment for locally advanced nasopharyngeal cancers (LA-NPC) [ 1 ]. Sadly, this treatment was accompanied by an increase in early complications like mucositis and …

The immune markers CD8 and FOXP3 correlated with EBNA1 or LMP1 in clinical nasopharyngeal specimens. Furthermore, all those markers were associated with nasopharyngeal cancer progression at least locally.

Xerostomia is a common side effect of nasopharyngeal carcinoma (NPC) radiotherapy (RT) [ 1 , 2 ]. It seriously affects the quality of life (QOL) of patients, including oral infection, eating problem, undernutrition, and insomnia [ 3 – 5 ].

Head and neck cancers (HNC) are the seventh most common malignancies worldwide and have been treated effectively by comprehensive sequence therapy, chiefly including surgery, chemotherapy and radiotherapy[ 1 , 2 ]. Over the past decades …

During the ASCO 2021 virtual meeting, multiple clinically relevant studies were presented addressing open questions regarding the therapy of nasopharyngeal carcinomas (NPC): Is immunotherapy plus chemotherapy the new first line standard of care …

Nasopharyngeal cancer (NPC) is the most frequent type of head and neck cancer in Southeast Asia and South China [ 1 – 3 ]. NPC has a higher incidence (86.4%) of cervical lymph node metastasis [ 4 ]. Intensity-modulated radiotherapy (IMRT) is the …

As reported by the International Agency for Research on Cancer, there were around 129,000 new cases of nasopharyngeal cancer diagnosed in 2018, which accounts for 0.7% of all types of cancers [ 1 ]. More than 70% of new cases are in east and …